Cue Biopharma Inc - CUE STOCK NEWS

Cue Biopharma (CUE) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will feature a pre-recorded fireside chat, available on its website starting November 22, 2021, at 10:00 a.m. EST. Cue Biopharma is focused on developing a novel class of injectable biologics that engage T cells, aiming to transform treatments for cancer and autoimmune diseases. The archived recording will be accessible for 90 days post-event.

Cue Biopharma (CUE) presented promising interim data for CUE-101, a monotherapy targeting HPV+ head and neck cancer, at SITC 2021. CUE-101 showed durable partial responses and favorable tolerability in its Phase 1 trial, with doses administered exceeding 190. Additionally, early results indicated potential activity when combined with pembrolizumab. CUE-102 demonstrated the ability to activate WT1-specific T cells, supporting its advancement towards clinical trials. The company plans to file for Investigational New Drug status for CUE-102 in Q1 2022, enhancing its development pipeline.

On November 10, 2021, Cue Biopharma (Nasdaq: CUE) announced its participation in two upcoming virtual fireside chats. The first will occur at the Stifel Healthcare Conference from November 15-17, while the second will take place at the Jefferies London Healthcare Conference from November 16-19. Cue Biopharma will update participants on its lead clinical program, CUE-101, and its related CUE-100 series pipeline, addressing treatments for HPV+ recurrent/metastatic head and neck cancer. Webcasts of these discussions will be available on the company's website.

Cue Biopharma announced promising findings from a study published in the Journal of Clinical Investigation, revealing that its Immuno-STAT™ Biologics can activate and expand anti-viral cytotoxic T cells targeting HIV and CMV. The study indicates potential for treating chronic viral infections without ex vivo manipulation of T cells, addressing a critical barrier in HIV treatment. Ongoing Phase 1 trials of CUE-101 also show positive outcomes in cancer therapy. The modularity of the Immuno-STAT platform suggests versatility in treating various infectious diseases.

On September 28, 2021, Cue Biopharma announced a publication in Scientific Reports detailing their innovative peptide-HLA-based platform technologies for selective immune modulation. The research emphasizes the potential of their Immuno-STAT and Neo-STAT platforms to develop targeted therapeutics for cancer, infectious, and autoimmune diseases. Key findings highlight their ability to safely activate T cells, enhancing therapeutic efficacy while minimizing adverse effects. The lead candidate, CUE-101, has shown promising results in clinical trials for HPV+ recurrent head and neck cancer.

Cue Biopharma announced the issuance of two new U.S. patents (Nos. 11,117,945 and 11,104,712) that enhance its intellectual property portfolio. These patents cover CUE-101, Cue's lead clinical candidate for treating HPV16-related cancers, currently in a Phase 1b trial. The drug has shown a 40% clinical benefit rate in early patients. The second patent focuses on the combination of CUE-101 with KEYTRUDA for similar cancer treatments. These developments bolster the company's position in immunotherapy and support its ongoing clinical trials.

Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in two virtual fireside chats at major healthcare conferences. The first is Baird's 2021 Global Healthcare Conference from September 14-15, where they will discuss their lead clinical program, CUE-101, targeting HPV+ recurrent/metastatic head and neck cancer. The second event is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 20-23. Presentations will highlight the latest updates and pipeline progress. Webcasts will be available for conference participants and archived for later viewing.

On August 17, 2021, Cue Biopharma provided a business and clinical update for Q2 2021, highlighting progress in its IL-2 based CUE-100 series, including a confirmed partial response in a patient from the CUE-101 trial. The trials for CUE-101 continue to advance, with a focus on its combination therapy with KEYTRUDA. Cue Biopharma reported approximately $2.7 million in collaboration revenue for Q2 2021, up from $1.1 million in Q2 2020. Operating expenses rose to $13 million, leading to a net loss of $10.3 million. The firm remains financially stable with $73.9 million in cash and equivalents.